Lowering the cutoff value for increment increases the sensitivity for the diagnosis of Lambert‐Eaton myasthenic syndrome

por Lipka, Alexander F., Titulaer, Maarten J., Tannemaat, Martijn R., Verschuuren, Jan J.G.M.
Publicado 2020

Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort

por Maddison, Paul, Lipka, Alexander F., Gozzard, Paul, Sadalage, Girija, Ambrose, Philip A., Lang, Bethan, Verschuuren, Jan J.
Publicado 2020

Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials

por Vrinten, Charlotte, Lipka, Alexander F, van Zwet, Erik W, Schimmel, Kirsten J M, Cornel, Martina C, Kuijpers, Marja R, Hekster, Yechiel A, Weinreich, Stephanie S, Verschuuren, Jan J G M
Publicado 2015

Long‐term follow‐up, quality of life, and survival of patients with Lambert‐Eaton myasthenic syndrome

por Lipka, Alexander F., Boldingh, Marion I., van Zwet, Erik W., Schreurs, Marco W.J., Kuks, Jan B.M., Tallaksen, Chantal M., Titulaer, Maarten J., Verschuuren, Jan J.G.M.
Publicado 2020

Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis

por Weinreich, Stephanie S., Vrinten, Charlotte, Kuijpers, Marja R., Lipka, Alexander F., Schimmel, Kirsten J. M., van Zwet, Erik W., Gispen-de Wied, Christine, Hekster, Yechiel A., Verschuuren, Jan J. G. M., Cornel, Martina C.
Publicado 2017